# What did the CJC-1295 trials in people measure?

Published November 15, 2026 · Updated November 15, 2026 · Data as of November 15, 2026

In a randomized trial in healthy adults, one [CJC-1295 (with DAC)](https://pepbank.io/p/cjc-1295) injection raised mean plasma growth hormone (GH) 2- to 10-fold. The rise lasted 6 days or more. [1] In the same trial in people, insulin-like growth factor I (IGF-I) rose 1.5- to 3-fold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days. [1] No serious adverse reactions were reported in that trial in people. [1]

## Key points

- In a randomized trial in healthy adults, the estimated half-life of CJC-1295 was 5.8 to 8.1 days. [1]
- After repeated injections in a trial in healthy adults, mean insulin-like growth factor I (IGF-I) stayed above baseline for up to 28 days. [1]
- In a trial in healthy young men, serum spots of apolipoprotein A1 and transthyretin isoforms dropped in intensity one week after a CJC-1295 injection. [2]
- An immuno polymerase chain reaction (immuno-PCR) test confirmed CJC-1295 in blood samples in race horses after administration. [3]
- The PepBank regulatory record lists CJC-1295 (with DAC) as not approved for any use, as of October 9, 2026. [4]

## What did the trial in healthy adults find?

In a randomized trial in healthy adults, a single CJC-1295 injection raised mean plasma growth hormone (GH) 2- to 10-fold for 6 days or more. [1] Mean plasma IGF-I in that trial in people rose 1.5- to 3-fold for 9 to 11 days. [1]

The estimated half-life of CJC-1295 in the trial in people was 5.8 to 8.1 days. [1] After multiple doses in the trial in people, mean IGF-I stayed above baseline for up to 28 days. [1] No serious adverse reactions were reported in the trial in people. [1]

Curo, a peptide shop with the same owner as PepBank, has a related article. [CJC-1295 vs Ipamorelin: Two Pathways to One Pulse](https://curo.you/insights/cjc-1295-vs-ipamorelin-differences-and-the-blend)

## Did CJC-1295 change growth hormone pulses?

In a trial in healthy men, a single CJC-1295 injection raised overall mean GH by 46% one week later. [5] Basal (trough) GH in that trial in people rose 7.5-fold one week later. [5] IGF-I rose by 45% one week later in the same trial in people. [5]

The frequency and the magnitude of GH secretory pulses did not change in that trial in people. [5] The IGF-I increases in people did not correlate with any measure of GH secretion. [5]

## What serum protein changes appeared in young men?

In a trial in healthy young men, an apolipoprotein A1 isoform spot in serum showed decreased intensity one week after a CJC-1295 injection. [2] A transthyretin isoform spot in serum also dropped in intensity in that trial in people. [2] Beta-hemoglobin in serum went up after treatment in the same trial in people. [2]

In the trial in young men, a C-terminal fragment of albumin in serum went up after treatment. [2] A serum spot with an immunoglobulin fragment and another albumin fragment also went up in people. That spot had a linear relationship with IGF-1 levels. [2]

## How did studies in rats and horses detect CJC-1295?

In a rat injected with CJC-1295, a Western blot showed the peptide on the serum albumin band from 15 min onward. That species stayed in circulation in rats beyond 24 h. [6] In rats, CJC-1295 was present in plasma beyond 72 h. [6]

In rats given growth hormone-releasing hormone (GHRH) analogues into a vein, intact CJC-1295 was detected in plasma for at least 4 h. [7] No expected metabolite of CJC-1295 was confirmed in plasma in rats. [7] An immuno-PCR test confirmed CJC-1295 in blood samples in race horses after administration. [3]

## Where does CJC-1295 stand today?

The PepBank regulatory record lists CJC-1295 (with DAC) as not approved for any use, as of October 9, 2026. [4] PepBank holds 10 studies with results for CJC-1295 (with DAC), listed in [the CJC-1295 (with DAC) studies](https://pepbank.io/p/cjc-1295/studies). [8]

CJC-1295 (with DAC) is in the [list of peptides in PepBank](https://pepbank.io/peptides), with 1 registered trial in its records. [8] Its record holds 4 publications with findings in people. PepBank also has [CJC-1295 (with DAC) compared with sermorelin](https://pepbank.io/compare/cjc-1295-vs-sermorelin). [8]

## FAQ

### How many studies of CJC-1295 in people are there?

PepBank holds 4 publications with findings in people for CJC-1295 (with DAC), as of November 15, 2026. [8] Those publications hold 20 findings in people. [8] The records also hold 5 publications with findings in animals and 2 with laboratory findings in cells or tissue. [8] The trial registry records in PepBank list 1 registered trial. [8]

### Is CJC-1295 approved for medical use?

The PepBank regulatory record lists CJC-1295 (with DAC) as not approved for any use, as of October 9, 2026. That status covers all places in the record. [4] The trial registry records in PepBank list 1 registered trial that tests CJC-1295 (with DAC). [8] PepBank holds 4 publications with findings in people for it. [8]

### What do forum users say about CJC-1295?

In a study of online forum threads by people discussing female use, users said they chose CJC-1295 for several reasons. These were weight loss, muscle enhancement, youthful skin, improved sleep and injury healing. [9] In the same forum study of people, users raised concerns about dosage estimation, cycling and long-term consequences for women. [9]

### What did CJC-1295 do in mice?

In growth hormone-releasing hormone (GHRH) knockout mice, CJC-1295 given every 24 h gave normal body weight and normal body length. [10] In mice lacking brain M3 muscarinic receptors, it restored normal pituitary size and normal serum GH and IGF-1 levels. [11] In GHRH knockout mice, it also increased pituitary GH mRNA. [10]

## Sources

1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2005-12-13. https://pubmed.ncbi.nlm.nih.gov/16352683/ PMID 16352683. Evidence class: human.
2. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009-04-21. https://pubmed.ncbi.nlm.nih.gov/19386527/ PMID 19386527. Evidence class: human.
3. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug testing and analysis, 2018-12-25. https://pubmed.ncbi.nlm.nih.gov/30489688/ PMID 30489688. Evidence class: animal.
4. CJC-1295 (with DAC): regulatory status in PepBank. PepBank, 2026-10-09. https://pepbank.io/p/cjc-1295
5. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006-10-03. https://pubmed.ncbi.nlm.nih.gov/17018654/ PMID 17018654. Evidence class: human.
6. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005-04-07. https://pubmed.ncbi.nlm.nih.gov/15817669/ PMID 15817669. Evidence class: animal.
7. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and bioanalytical chemistry, 2016-02-15. https://pubmed.ncbi.nlm.nih.gov/26879649/ PMID 26879649. Evidence class: animal.
8. CJC-1295 (with DAC) in PepBank. PepBank, 2026-11-15. https://pepbank.io/p/cjc-1295
9. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016-01-15. https://pubmed.ncbi.nlm.nih.gov/26771670/ PMID 26771670. Evidence class: human.
10. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006-07-05. https://pubmed.ncbi.nlm.nih.gov/16822960/ PMID 16822960. Evidence class: animal.
11. Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. Proceedings of the National Academy of Sciences of the United States of America, 2009-03-30. https://pubmed.ncbi.nlm.nih.gov/19332789/ PMID 19332789. Evidence class: animal.

How this article is made: PepBank writes its articles from the studies and records in its database. Each claim links to its source. [Read how PepBank collects and classes evidence.](https://pepbank.io/methods)

Canonical: https://pepbank.io/blog/what-did-the-cjc-1295-trials-in-people-measure

This is not medical advice.
